Related references
Note: Only part of the references are listed.Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension
Tatsuhiko Azegami et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2019)
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Yu Ho Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Modelling diabetic nephropathy in mice
Kengo Azushima et al.
NATURE REVIEWS NEPHROLOGY (2018)
RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-beta and Increasing Resistance to Apoptosis
Shinji Hagiwara et al.
DIABETES (2018)
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Michitsugu Kamezaki et al.
SCIENTIFIC REPORTS (2018)
Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy
Zhangjian Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Nanogel-based nasal ghrelin vaccine prevents obesity
T. Azegami et al.
MUCOSAL IMMUNOLOGY (2017)
Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling
Biyu Hou et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Diabetes and CKD in the United States Population, 2009-2014
Leila R. Zelnick et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Diabetic Kidney Disease Challenges, Progress, and Possibilities
Radica Z. Alicic et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy
Takanori Matsui et al.
DIABETES (2017)
Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study
Maryam Afkarian et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Nonadherence of Oral Antihyperglycemic Medication Will Increase Risk of End-Stage Renal Disease
Po-Ya Chang et al.
MEDICINE (2015)
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Sih Min Tan et al.
DIABETES (2014)
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Katherine R. Tuttle et al.
DIABETES CARE (2014)
Longistatin in tick saliva blocks advanced glycation end-product receptor activation
Anisuzzaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Dual Inhibition of Classical Protein Kinase C-α and Protein Kinase C-β Isoforms Protects Against Experimental Murine Diabetic Nephropathy
Jan Menne et al.
DIABETES (2013)
Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products
Laure Yatime et al.
FEBS JOURNAL (2013)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice
Anna M. D. Watson et al.
DIABETES (2012)
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
Caroline S. Fox et al.
LANCET (2012)
Deletion of Von Hippel-Lindau in Glomerular Podocytes Results in Glomerular Basement Membrane Thickening, Ectopic Subepithelial Deposition of Collagen al α1α2α1(IV), Expression of Neuroglobin, and Proteinuria
Brooke M. Steenhard et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 Mouse
Nina Reiniger et al.
DIABETES (2010)
The 1.5 Å Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding
HaJeung Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Solution Structure of the Variable-Type Domain of the Receptor for Advanced Glycation End Products: New Insight into AGE-RAGE Interaction
Shigeyuki Nlatsumoto et al.
BIOCHEMISTRY (2008)
LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat
J. L. Figarola et al.
DIABETOLOGIA (2008)
Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives
Allison F. Williams et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2008)
Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE)
Jingjing Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase
Zhongyi Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
RAGE control of diabetic nephropathy in a mouse model -: Effects of RAGE gene disruption and administration of low-molecular weight heparin
Khin-Mar Myint et al.
DIABETES (2006)
Mouse models of diabetic nephropathy
MD Breyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
A Flyvbjerg et al.
DIABETES (2004)
Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes
S Okada et al.
DIABETES (2003)
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE - A mechanism for amplification of inflammatory responses
G Basta et al.
CIRCULATION (2002)
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
TP Degenhardt et al.
KIDNEY INTERNATIONAL (2002)
Advanced glycation end products and the progressive course of renal disease
A Heidland et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice
M Katoh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
